Showing 1 - 4 of 4 Transplant Trials

Status: Open Not Enrolling

Investigator: Richard Knight

Study Coordinator: Adam Daniels

Phone: 713.441.6232

The purpose of this study is to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor. This study will also e ... Read more >

Status: Open Not Enrolling

Investigator: Richard Knight

Study Coordinator: Alejandro De La Torre

Phone: 713.441.6396

The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant. ... Read more >

Status: Enrolling

Investigator: Barry Trachtenberg

Study Coordinator: Marcos DeOliveira

Phone: 171.344.19837

The purpose of this study is to evaluate the efficacy and safety of a single transendocardial delivery in the cardiac catheterization laboratory of human bone marrow-derived allogeneic MPCs (rexlemestrocel-L) for improvement in clinical outcomes ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Darrel Cleere

Phone: 713.441.6232

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged cour ... Read more >

Live Chat Available